Pfizer Inc. (PFE) and Astellas Pharma Announce Survival Results from Phase 3 EMBARK Study

​Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 19, Pfizer Inc. (NYSE:PFE) and Astellas Pharma US Inc. announced final overall survival results from their Phase 3 EMBARK study.

​The study evaluated XTANDI in combination with leuprolide as a monotherapy for men with non-metastatic hormone-sensitive prostate cancer. The results showed the therapy reduced the risk of death by 40.3% compared to leuprolide alone. Moreover, the mean follow-up time for XTANDI in combination with leuprolide was 94.2 months. The safety profile of the treatment was also consistent with that observed at the primary EMBARK analysis.

​Johanna Bendell, M.D., Chief Development Officer, Oncology, Pfizer, said

“With up to 90 percent of men with high-risk BCR developing metastatic disease, early intervention with effective therapy is critical. The final analysis from EMBARK shows that XTANDI plus leuprolide improved outcomes and extended lives for men facing high-risk BCR after local therapy with curative intent.”

​​Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing medicines.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.